These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 33827932)
1. Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres. Bonacina R; Indini A; Massazza G; Rulli E; Gianatti A; Mandalà M; J Clin Pathol; 2022 Aug; 75(8):555-559. PubMed ID: 33827932 [TBL] [Abstract][Full Text] [Related]
3. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas. Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas. do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709 [TBL] [Abstract][Full Text] [Related]
5. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice. Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543 [TBL] [Abstract][Full Text] [Related]
7. Genetic Study of Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576 [No Abstract] [Full Text] [Related]
8. Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration. Hirschhorn A; Campino GA; Vered M; Greenberg G; Yacobi R; Yahalom R; Barshack I; Toren A; Amariglio N; Rechavi G J Tissue Eng Regen Med; 2021 Dec; 15(12):1155-1161. PubMed ID: 34599642 [TBL] [Abstract][Full Text] [Related]
9. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population. Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063 [TBL] [Abstract][Full Text] [Related]
10. Analysis of BRAF V600E expression and disease-free survival in patients with ameloblastoma. Kunmongkolwut S; Chaisuparat R Int J Oral Maxillofac Surg; 2022 Aug; 51(8):1034-1042. PubMed ID: 34998647 [TBL] [Abstract][Full Text] [Related]
11. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332 [TBL] [Abstract][Full Text] [Related]
12. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition. Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301 [TBL] [Abstract][Full Text] [Related]
13. Machine learning-based radiomics for predicting BRAF-V600E mutations in ameloblastoma. Li W; Li Y; Liu X; Wang L; Chen W; Qian X; Zheng X; Chen J; Liu Y; Lin L Front Immunol; 2023; 14():1180908. PubMed ID: 37646022 [TBL] [Abstract][Full Text] [Related]
14. Association of MDM2 Overexpression in Ameloblastomas with Tosios KI; Kalogirou EM; Koutlas IG Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916 [TBL] [Abstract][Full Text] [Related]
15. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution. Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757 [TBL] [Abstract][Full Text] [Related]
16. The importance of BRAF-V600E mutation to ameloblastoma metabolism. Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334 [TBL] [Abstract][Full Text] [Related]
17. Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking. Guan P; Wong SF; Lim JQ; Ng CCY; Soong PL; Sim CQX; Ong CK; Rajasegaran V; Myint SS; Lee JY; Tan HK; Iyer NG; Soo KC; Teh BT; Tay ABG J Dent Res; 2019 Jun; 98(6):652-658. PubMed ID: 30917298 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach. Grynberg S; Vered M; Shapira-Frommer R; Asher N; Ben-Betzalel G; Stoff R; Steinberg Y; Amariglio N; Greenberg G; Barshack I; Toren A; Yahalom R; Schachter J; Rechavi G; Hirschhorn A; Abebe Campino G J Natl Cancer Inst; 2024 Apr; 116(4):539-546. PubMed ID: 37966914 [TBL] [Abstract][Full Text] [Related]
19. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital. Kelppe J; Thorén H; Ristimäki A; Haglund C; Sorsa T; Hagström J Oral Dis; 2019 May; 25(4):1169-1174. PubMed ID: 30811720 [TBL] [Abstract][Full Text] [Related]